Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer

References

• National Comprehensive Cancer NetworkNCCN Clinical Practice Guidelines in Oncology: Breast CancerFort Washington, PANational Comprehensive Cancer Network2014 Available from: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdfAccessed June 10, 2014
   Google Scholar
• WolffACHammondMESchwartzJNAmerican Society of Clinical Oncology/College of American PathologistsAmerican Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancerArch Pathol Lab Med20071311184319548375
   PubMed Web of Science ®Google Scholar
• College of American PathologistsASCO-CAP HER2 Test Guideline Recommendations: Summary of Guideline 2007 and 2013 RecommendationsNorthfield, ILCollege of American Pathologists2013 Available from: http://www.cap.org/apps/docs/committees/immunohistochemistry/summary_of_recommendations.pdfAccessed September 18, 2014
   Google Scholar
• ClayMRIberriDJBangsCDCherryAJensenKCClinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institutionAm J Surg Pathol201337112012723108020
   PubMed Web of Science ®Google Scholar
• MojaLTagliabueLBalduzziSTrastuzumab containing regimens for early breast cancerCochrane Database Syst Rev20124CD00624322513938
   PubMed Web of Science ®Google Scholar
• MitriZConstantineTO’ReganRThe HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapyChemother Res Pract2012201274319323320171
   PubMedGoogle Scholar
• DekkerTJBorgSTHooijerGKDetermining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approachBreast Cancer Res2012143R9322694844
   PubMed Web of Science ®Google Scholar
• GownAMCurrent issues in ER and HER2 testing by ICH in breast cancerMod Pathol200821Suppl 2S8S1518437174
   PubMed Web of Science ®Google Scholar
• WolffACHammondMEHicksDGAmerican Society of Clinical OncologyCollege of American PathologistsRecommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateArch Pathol Lab Med2014138224125624099077
   PubMed Web of Science ®Google Scholar
• WolffACHammondMEHicksDGAmerican Society of Clinical OncologyCollege of American PathologistsRecommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateJ Clin Oncol201331313997401324101045
   PubMed Web of Science ®Google Scholar
• WolffACHammondMESchwartzJNAmerican Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancerJ Clin Oncol200725111814517159189
   PubMed Web of Science ®Google Scholar
• CharlsonMEPompeiPAlesKLMacKenzieCRA new method of classifying prognostic comorbidity in longitudinal studies: development and validationJ Chronic Dis19874053733833558716
   PubMedGoogle Scholar
• CroninKAHarlanLCDoddKWAbramsJSBallard-BarbashRPopulation-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the USCancer Invest201028996396820690807
   PubMed Web of Science ®Google Scholar
• PariseCABauerKRBrownMMCaggianoVBreast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999–2004Breast J200915659360219764994
   PubMed Web of Science ®Google Scholar
• BarronJJCzirakyMJWeismanTHicksDGHER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environmentOncologist200914876076819684074
   PubMed Web of Science ®Google Scholar
• BastRCJrRavdinPHayesDFAmerican Society of Clinical Oncology Tumor Markers Expert Panel2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical OncologyJ Clin Oncol20011961865187811251019
   PubMed Web of Science ®Google Scholar
• GoddardKABowlesEJFeigelsonHSUtilization of HER2 genetic testing in a multi-institutional observational studyAm J Manag Care2012181170471223198713
   PubMed Web of Science ®Google Scholar
• PariseCABauerKRCaggianoVVariation in breast cancer subtypes with age and race/ethnicityCrit Rev Oncol Hematol2010761445219800812
   PubMed Web of Science ®Google Scholar
• FehrenbacherLHabelLACapraAMAnthonyALiXIncidence, demographic and tumor characteristics of HER2-positive invasive breast cancer in a large, unselected population, 2000–2006Cancer Research200969(24)Supplement 3
   Web of Science ®Google Scholar
• KonecnyGPaulettiGPegramMQuantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancerJ Natl Cancer Inst200395214215312529347
   PubMed Web of Science ®Google Scholar
• VialeGControversies in testing for HER2American Society of Clinical Oncology 2011 Educational Book. 47th Annual MeetingJune 3–7, 2011Chicago, ILAlexandria, VAAmerican Society of Clinical Oncology2011
   Google Scholar
• SchalperKAKumarSHuiPRimmDLGershkovichPA retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteriaArch Pathol Lab Med2014138221321924164555
   PubMed Web of Science ®Google Scholar
• ShahSSKetterlingRPGoetzMPImpact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancerHum Pathol201041110310619762065
   PubMed Web of Science ®Google Scholar
• CuriglianoGVialeGBagnardiVClinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancerJ Clin Oncol200927345693569919884553
   PubMed Web of Science ®Google Scholar
• Gonzalez-AnguloAMLittonJKBroglioKRHigh risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smallerJ Clin Oncol200927345700570619884543
   PubMed Web of Science ®Google Scholar
• CarlsonRWMoenchSJHammondME NCCN HER2 Testing in Breast Cancer Task ForceHER2 testing in breast cancer: NCCN Task Force report and recommendationsJ Natl Compr Canc Netw20064Suppl 3S1S22 quiz S23–S24
   PubMedGoogle Scholar
• OhlschlegelCZahelKKradolferDHellMJochumWHER2 genetic heterogeneity in breast carcinomaJ Clin Pathol201164121112111622011446
   PubMed Web of Science ®Google Scholar
• Vanden BemptIVan LooPDrijkoningenMPolysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testingJ Clin Oncol200826304869487418794552
   PubMed Web of Science ®Google Scholar
• VranicSTeruyaBRepertingerSUlmerPHagenkordJGatalicaZAssessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17Cancer20111171485320803611
   PubMed Web of Science ®Google Scholar